Chinese AI-Driven Biotech EpiGenic Therapeutics Secures $60M Series B Funding and Files for IPO
Epigenic
Gene Editing Technology Developer
9On the 8th day of the month, a clinical-stage innovative drug research and development companyEpigenicEpigenic Therapeutics, Inc. (hereinafter referred to as “Epigenic), announced the completion$60 Million Series BFinancing (approximately RMB 428 million).
This round of financing was led byLongpan InvestmentLed by, original investorsQiming Venture PartnersAndOrbiMedContinue to invest and introduce Hong Kong-Guangdong capital and well-known industry investment institutions to participate together.
EpigenicEpigenic was founded in 2021, with its headquarters located in Shanghai. The company was jointly established by a technical team from the Chinese Academy of Sciences and senior drug development experts.Dedicated to developing the next generation of epigenetic regulation technology for the treatment of chronic diseases.
The funds from this round of financing will be mainly used to support innovative epigenetic drugs.EPI-003In the clinical cure of chronic hepatitis B andEPI-001Continuous Clinical Development in the Treatment of Hypercholesterolemia.
In addition, the funds will also be used to rapidly advance multiple preclinical projects and continuously build technology platforms, injecting strong momentum into the company's in-depth efforts in the field of epigenetic drug research and development.
The company owns independent intellectual property rightsEPIREG™ Technology Platform optimizes CRISPR-Cas components through AI algorithms. With precise DNA methylation and histone modification, it can silence target genes efficiently, durably, and specifically. Compared to traditional gene-editing tools that cut DNA, it provides a safer and revolutionary innovative treatment option for patients with chronic diseases.
Notably, Epigenic's self-developed in vivo LNP delivery platform—EpiTax™—enables precise delivery of the EPIREG™ tool to the liver as well as multiple extrahepatic target organs, further expanding the application scope of the EPIREG™ tool in disease treatment. This brings new possibilities for treatments across a broader range of disease areas, making the company’s technology portfolio more comprehensive and competitive.
In addition, the AIAID™ platform established by Epigenic empowers the design of epigenetic regulatory drug molecules, target selection, and precise regulation.
This platform is equipped with a self-developed foundational large model for epigenetics, providing precise underlying data and algorithmic support; through a multi-agent collaborative virtual laboratory, it autonomously accomplishes key tasks such as target discovery, target research, accessibility prediction, sgRNA design and evaluation, virtual epigenetic regulation, and multi-omics analysis; and accelerates the discovery, iteration, and performance optimization process of EPIREG™ by leveraging AI-driven de novo protein design and AI-directed evolution technologies.
Recommended Reading
